CTRI/2022/05/042597招募中不适用
A double-blind, randomized, placebo-controlled comparative study to evaluate the safety and efficacy of Ashwagandha whole plant extract in patients with insomnia
SamiSabinsa Group Limited2 个研究点 分布在 1 个国家目标入组 86 人开始时间: 2022年2月6日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 86
- 试验地点
- 2
- 主要终点
- 1. Mean change in the Sleep Condition Indicator (SCI).
研究概览
简要总结
All eligible patients who meet the Inclusion and Exclusion criteria will be enrolled in the study. All patients of this study will be randomised to either Ashwagandha 500 mg once a day or Placebo of 500mg once a day for a period of 30 days. 2 ml of saliva is taken in the morning (8:00 am) in a fasting state for salivary cortisol. Patient visits will be as follows on Screening Visit- visit 1(Day -5), Baseline -Visit 2 (Day 0), Visit 3 (Day 7) +/- 3 days; and Visit 4 (Day 30) +/- 5 days.
Telephonic follow-up after 10 days from the last visit to know the Adverse event and overall wellbeing of the patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Participant, Investigator and Outcome Assessor Blinded
入排标准
- 年龄范围
- 18.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •1.Male and Female participant above 18 to 60 years of age and willing to give written inform Consent.
- •2.Perceived total sleep time of more than 6 hours per night 3.Patient with history of self-reported primary insomnia Or with diagnosis of primary insomnia (as defined by the Diagnostic and Statistical Manual for Mental Disorders-IV [DSM-IV-TR].
排除标准
- •1.Female who are pregnant, breast feeding or not willing to use adequate contraception during the course of the study.
- •2.BMI more than or equal to 18.5 or less than or equal to 35 kg/m2 3.Patient with psychiatric illness or concomitant disorder or any other condition that could potentially disturb or have impact on sleep.
- •4.Patients using tobacco products or caffeinated beverages during night awakenings.
- •5.Patient with diagnostic history of serious illness liver, kidney, heart, thyroid or bone marrow.
- •6.Patients on any medication for insomnia.
- •7.Patients with liver function parameters (total bilirubin, conjugated bilirubin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase) more than 2 times upper limit of normal.
- •8.Patients using any sedative hypnotic drugs including benzodiazepines, non-benzodiazepine synthetic drugs, herbal and OTC products.
- •9.Patients worked in night shifts within 5 days of screening or intended to do so during the course of the study.
- •10.Patients with history of alcohol abuse or drugs abuse.
- •11.Patients who were using any other medication that are known to influence sleep but could not be withdrawn.
- •12.Patients undergoing treatment for any other systemic illness.
- •13.Patients who are participated in another investigational drug had been used within three months prior to screening in this study.
- •14.Patients with known allergic reaction to the investigational product.
- •15.Patients who could not be relied upon to comply with the study procedures.
结局指标
主要结局
1. Mean change in the Sleep Condition Indicator (SCI).
时间窗: 1. Day 0, Day 7 and Day 30. | 2. Day 0, Day 7 and Day 30.
2. Mean change in total sleep time
时间窗: 1. Day 0, Day 7 and Day 30. | 2. Day 0, Day 7 and Day 30.
次要结局
- 1. Mean change in average sleep latency per night(2. Mean change in average no of night-time awakenings per night.)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
Unknown
Effectiveness of Ashwagandha Serum on the Hair Health in AdultsCTRI/2023/06/053920Ixoreal Biomed Private Limited60
进行中（未招募）
不适用
To Evaluate the Effects of Ashwagandha capsule on Skin and Hair Health in Healthy adultsCTRI/2022/09/045770Ixoreal Biomed Private Limited92
撤回
2 期
Valiloxybate (XW10172 MR) Efficacy and Safety Parkinson's Disease StudyExcessive Daytime SomnolenceParkinson DiseaseNCT05056194XWPharma70
已完成
2 期
Study of Plozasiran (ARO-APOC3) in Adults With Mixed DyslipidemiaMixed DyslipidemiaNCT04998201Arrowhead Pharmaceuticals353
撤回
3 期
Fentanyl Sublingual Spray for the Treatment of Acute Procedure-related Pain in a Monitored SettingChronic PainNCT02138409INSYS Therapeutics Inc